ProKidney Corp.

NasdaqCM PROK

ProKidney Corp. Market Capitalization on January 14, 2025: USD 1.81 B

ProKidney Corp. Market Capitalization is USD 1.81 B on January 14, 2025, a 178.44% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ProKidney Corp. 52-week high Market Capitalization is USD 2.28 B on December 16, 2024, which is 26.03% above the current Market Capitalization.
ProKidney Corp. 52-week low Market Capitalization is USD 549.90 M on February 13, 2024, which is -69.65% below the current Market Capitalization.
ProKidney Corp. average Market Capitalization for the last 52 weeks is USD 1.18 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: PROK

ProKidney Corp.

CEO	Dr. Bruce Culleton M.D.
IPO Date	June 30, 2021
Location	United States
Headquarters	2000 Frontis Plaza Blvd.
Employees	163
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key trends

Past 5 years